We support value-based cancer care
with the goal of improving patient outcomes
and reducing the lifetime cost of care
Cancer incidence and survivorship continue to grow. Cancer treatment is complex and expensive. The burden of cancer is accelerating. On the individuals that are diagnosed with cancer. On the survivors that are living with their disease for longer periods of time. On the clinicians that treat patients. And the payers that finance their care.


We focus the passion of our people and the
commitment of our company on making a difference
in the lives of cancer patients
Radialogica’s mission is to empower healthcare providers and payers to manage the care and cost of cancer treatment and survivorship. We provide tools, evidence and insight to elevate and standardize quality of care and reduce the physical and financial burden of cancer survivorship.


As a company and as a team we strive to infuse
honesty, empathy, creativity, curiosity and accountability
in everything we do
Radialogica is a purpose-driven company. Our values and priorities infuse our culture and our work. We’re here to serve cancer patients and survivors. Full stop. We work hard. We work smart. We work as a team. And we fully embrace the larger meaning and purpose of our work.


Radialogica was founded and is led
by healthcare clinicians and executives
with extensive experience and insight
Our organization benefits from expert product design input derived from years of academic research and clinical practice; skilled software engineering resources with significant radiotherapy-specific domain expertise; longstanding relationships with corporate and clinical collaboration partners; a substantial regulatory infrastructure and robust quality management system; and a demonstrated track record of commercial success in the industry.
Andy serves as Chief Executive Officer of Radialogica and has nearly twenty years of executive leadership and private equity investment experience in the healthcare industry.
  • Andy previously served as President and Chief Executive Officer of CMS, Inc., the radiotherapy treatment planning company, where he led the successful strategic repositioning and operational restructuring of the business and subsequent sale to Elekta AB.
  • Prior to joining CMS he served for twelve years as an executive of Brown Brothers Harriman in its private equity investment group, with primary responsibility for Brown Brothers' healthcare-oriented venture and growth capital investments.
  • He also served on the Board of Directors of ProTom International, Inc. and the ASTRO Corporate Advisory Council.
  • Andy is a Phi Beta Kappa and summa cum laude graduate of Bowdoin College, and earned his MBA from the Wharton School of the University of Pennsylvania.
Scott is a co-founder of Radialogica and serves as Chief Operating Officer.
  • Scott previously served as Chief of Clinical Development in the Department of Radiation Oncology at the Washington University School of Medicine and Siteman Cancer Center.
  • Prior to joining the faculty at Washington University, he served as Senior Vice President of Clinical Design and Research at CMS, Inc., before which he was a Research Fellow at the Memorial Sloan-Kettering Cancer Center in New York City.
  • Scott’s research interests focus on the application of Bayesian statistics and decision theory to problems in Oncology. He received his Ph.D. from the University of Tennessee and his MBA from the Olin School of Business at Washington University in St. Louis.
Cliff is Board Certified in Radiation Oncology and serves as Chief Medical Officer of Radialogica.
  • Cliff is also a Professor in the Department of Radiation Oncology and the Department of Internal Medicine (Division of Cardiology) at Washington University in St. Louis.
  • Cliff serves as Chief of Service for Thoracic Radiation Oncology and Stereotactic Body Radiotherapy, Director of Clinical Trials and Co-Director of the Center for Noninvasive Cardiac Radioablation (CNCR).
  • Cliff’s areas of clinical interest include lung and esophageal cancers, brain and spinal tumors, stereotactic radiotherapy and noninvasive cardiac radioablation.
  • Cliff’s research focuses extensively on the integration of clinical and dosimetric data for modeling of patient outcomes.
  • Cliff is also highly involved in the development and conduct of clinical trials, and is a co-chair on multiple national cooperative group trials.
  • Cliff received his medical degree from Case Western Reserve University School of Medicine and completed his residency at the Cleveland Clinic.